TW202229359A - Her2標靶藥物 - Google Patents

Her2標靶藥物 Download PDF

Info

Publication number
TW202229359A
TW202229359A TW110144472A TW110144472A TW202229359A TW 202229359 A TW202229359 A TW 202229359A TW 110144472 A TW110144472 A TW 110144472A TW 110144472 A TW110144472 A TW 110144472A TW 202229359 A TW202229359 A TW 202229359A
Authority
TW
Taiwan
Prior art keywords
amino acid
antibody
seq
acid sequence
antigen
Prior art date
Application number
TW110144472A
Other languages
English (en)
Chinese (zh)
Inventor
加藤幸成
金子美華
中山大介
黑木雅禮
Original Assignee
日商小野藥品工業股份有限公司
國立大學法人東北大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商小野藥品工業股份有限公司, 國立大學法人東北大學 filed Critical 日商小野藥品工業股份有限公司
Publication of TW202229359A publication Critical patent/TW202229359A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW110144472A 2020-11-30 2021-11-29 Her2標靶藥物 TW202229359A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020198044 2020-11-30
JP2020-198044 2020-11-30
JP2021-110912 2021-07-02
JP2021110912 2021-07-02

Publications (1)

Publication Number Publication Date
TW202229359A true TW202229359A (zh) 2022-08-01

Family

ID=81754499

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110144472A TW202229359A (zh) 2020-11-30 2021-11-29 Her2標靶藥物

Country Status (10)

Country Link
US (2) US20240002531A1 (enExample)
EP (1) EP4253420A4 (enExample)
JP (2) JP7393774B2 (enExample)
KR (1) KR20230114747A (enExample)
AU (1) AU2021387127A1 (enExample)
CA (1) CA3199473A1 (enExample)
IL (1) IL303154A (enExample)
MX (1) MX2023005864A (enExample)
TW (1) TW202229359A (enExample)
WO (1) WO2022114163A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118871471A (zh) 2022-04-08 2024-10-29 菲特治疗公司 用于肿瘤靶向的嵌合抗原受体
AU2023249802A1 (en) * 2022-04-08 2024-10-24 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
SI2330131T1 (sl) 2009-12-07 2015-02-27 Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants Protitelesa proti HER2 skrajšani varianti CTF-611
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2019246021A1 (en) * 2018-06-18 2019-12-26 Dxdiscovery, Inc. Methods and compositions for pertussis diagnosis
CN118871471A (zh) * 2022-04-08 2024-10-29 菲特治疗公司 用于肿瘤靶向的嵌合抗原受体

Also Published As

Publication number Publication date
JPWO2022114163A1 (enExample) 2022-06-02
US20240002531A1 (en) 2024-01-04
WO2022114163A1 (ja) 2022-06-02
EP4253420A1 (en) 2023-10-04
JP2024020436A (ja) 2024-02-14
KR20230114747A (ko) 2023-08-01
EP4253420A4 (en) 2024-11-06
AU2021387127A1 (en) 2023-06-22
IL303154A (en) 2023-07-01
US11981747B1 (en) 2024-05-14
CA3199473A1 (en) 2022-06-02
JP7393774B2 (ja) 2023-12-07
MX2023005864A (es) 2023-06-05

Similar Documents

Publication Publication Date Title
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
CN113227135B (zh) 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
KR101854443B1 (ko) 항-her2 항체 및 이의 접합체
KR102029248B1 (ko) 암세포 특이적 항체, 항암제 및 암 검사 방법
RS56219B1 (sr) Antitela protiv csf-1r
WO2016171242A1 (ja) Ｅｐｈａ２の検出
JPWO2020026987A1 (ja) 抗ｒｏｒ１モノクローナル抗体およびその機能的断片、遺伝子、薬剤デリバリー組成物、並びに、医薬組成物
US11981747B1 (en) HER2 targeting agent
US20230365676A1 (en) Cd33 antibodies
CN107108734B (zh) 单克隆抗gpc-1抗体和其用途
CN115505043A (zh) 特异性结合糖基化ceacam5的抗体
CN116472350A (zh) 新型抗cldn18抗体
CA3089300A1 (en) Antibody, functional fragment or probe thereof against tumour antigens
WO2017065493A1 (ko) 항-cd43 항체 및 이의 암 치료 용도
WO2022175481A1 (en) Vegfa-binding molecules
CN115819596A (zh) 一种靶向人ceacam5/6的抗体、制备方法和应用
CN117088981A (zh) 抗b7-h3的单链抗体
CN116615239A (zh) Her2靶向剂
HK40091222A (zh) Her2靶向剂
JP2019050737A (ja) Ｃｄ４４陽性ｔｍｅｍ−１８０陽性のがん細胞由来微粒子、これを用いた抗ｔｍｅｍ−１８０抗体療法が有効ながん患者の選別方法、選別された患者に対する抗ｔｍｅｍ−１８０抗体を含む抗がん剤、および前記方法に用いるキット
CN114907478A (zh) 结合lag-3的抗体及其用途
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
TW202509076A (zh) 抗claudin18.2抗體及其製造和使用方法
KR20250160321A (ko) 항-메소텔린 항체 및 이의 용도